Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time? 

A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial.

Carry on – or close it down. This is the dilemma life science VC’s face when experiencing a “failed experiment” in a portfolio company and the decision-complexity can sometimes be increased by commitments and investments already made but yet unspent by the company.

In our analysis of VC Losses, described in our previous two posts, we did not include companies with accumulated losses to VC’s below EUR 2M. The rationale being that they can be absorbed by most VC’s without significant impact to overall portfolio performance. About 75% of all losses in therapeutics have accumulated investments below EUR 2M, indicating that many seed funded companies do not have the quality to get substantial VC funding – or simply fail early.

For the remaining 154 companies in our dataset, with >EUR 2M losses to investors, we wanted to understand whether the time we hold on before cutting our losses correlates with the phase of development. One would expect a longer time in pre-clinical development while trying to resolve difficult biology and a shorter additional time to a loss after a relatively addressable phase I that may fail. We were thinking 3-4 years to fail in preclinic and an additional 1-2 years if failing in phase I and having to take the loss. 

Below we have plotted the “time to loss” after first investment, relative to the clinical stage, when taking the loss. To our surprise, the time to loss is close to 10 years regardless of stage! 

As you may know, most venture funds have a 10 year outlook with commitment to close the funds after 10 years. Is the overlap a coincidence? – or are life science VCs not sufficiently disciplined in closing down failing investments before they have to? Or do VC’s believe that the “second shot on goal” has a higher likelihood of success and justifies the additional investment? 

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that liver imaging drug candidate, Orviglance®, significantly improved visualization of focal liver lesions, successfully...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of...

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of a EUR 54 million upsized financing. The financing includes investment from new investors EQT...

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and...

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

5 latest articles

The VC summer dream – the Fund Returner

Sunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today primarily an early stage (pre-clinical/phase...

Are we making a tangible difference?

We are a Life Science Venture Capital with a passion for investing in drug development, both because it is extremely exciting but also because we contribute to moving new therapies closer to patients with severe, untreated diseases – we matter! – we make a tangible...

Sunstone has supported and funded companies that have been the originator of 20 life-changing products

Since the inception in 2007, Sunstone Life Science Ventures (Sunstone) has co-created, supported and funded life science companies that have been the originator of 20 life-changing products approved for the treatment or diagnosis of patients with cardiovascular,...

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...

Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses?  Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1)...